Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Csl Ltd (CSL.AX)

Csl Ltd (CSL.AX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [ASX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [ASX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Csl Ltd 655 Elizabeth Street Melbourne VIC 3000 AUS

https://www.csl.com P: +61 393891911 F: +61 393891434

Sector:

N/A

INDUSTRY GROUPING:

N/A

Description:

CSL is one of the largest global biotech companies and has three main segments. CSL Behring either uses plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders, and neurological indications. CSL Seqirus is the world's second-largest influenza vaccination business and was acquired in fiscal 2016. CSL Vifor is an iron deficiency and nephrology business and was acquired in fiscal 2023. CSL has a strong R&D track record, and the product portfolio and pipeline include nonplasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and a quarter in Europe.

Key Statistics

Overview:

Market Capitalization, $K 66,755,622
Shares Outstanding, K 485,319
% of Institutional Shareholders 34.50%

Financials:

Annual Sales, $ 15,430 M
Annual Net Income, $ 3,002 M
Last Quarter Sales, $ 8,213 M
Last Quarter Net Income, $ 2,007 M

Growth:

1-Year Return -42.71%
3-Year Return -54.56%
5-Year Return -49.83%
5-Year Revenue Growth 11.14%
5-Year Earnings Growth 5.98%
5-Year Dividend Growth 8.23%

Per-Share Information:

Most Recent Earnings 4.13 on 02/11/25
Next Earnings Date N/A
Earnings Per Share ttm 6.17
Annual Dividend & Yield (Paid) 2.81 (3.10%)
Annual Dividend & Yield (Fwd) 3.62 (3.10%)
Most Recent Dividend 1.810 on 03/10/26
Next Ex-Dividends Date 03/10/26
Dividend Payable Date 04/09/26
Dividend Payout Ratio 45.49%
Most Recent Split 3-1 on 10/18/07

CSL.AX Ratios

Ratio
Price/Earnings ttm 15.89
Price/Earnings forward 18.73
Return-on-Equity % 16.36%
Return-on-Assets % 7.75%
Profit Margin % 19.46%
Debt/Equity 0.55
Price/Sales 3.10
Price/Book 2.55
Book Value/Share 53.58
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.